The estimated Net Worth of Elaine J Heron is at least $17.2 Milión dollars as of 3 June 2024. Elaine Heron owns over 5,047 units of Biomarin Pharmaceutical stock worth over $8,638,065 and over the last 21 years he sold BMRN stock worth over $8,111,157. In addition, he makes $477,020 as Independent Director at Biomarin Pharmaceutical.
Sign up
Elaine Heron BMRN stock SEC Form 4 insiders trading
Elaine has made over 15 trades of the Biomarin Pharmaceutical stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 5,047 units of BMRN stock worth $318,466 on 3 June 2024.
The largest trade he's ever made was selling 135,000 units of Biomarin Pharmaceutical stock on 7 November 2012 worth over $6,316,650. On average, Elaine trades about 7,437 units every 155 days since 2003. As of 3 June 2024 he still owns at least 101,888 units of Biomarin Pharmaceutical stock.
You can see the complete history of Elaine Heron stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Elaine Heron biography
Dr. Elaine J. Heron, Ph.D., is an Independent Director of Biomarin Pharmaceutical Inc. Dr. Heron joined our Board in July 2002 and serves as the Chair of the Corporate Governance and Nominating Committee. Dr. Heron served as Chair and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a private early-stage drug development company, from February 2009 until October 2015, and she continues to serve as member of that company’s board. She is also a Director of Vala Sciences Inc., a private life science tools company, Palvella Therapeutics, a private early-stage therapeutics company and Dropworks, Inc., a medical diagnostic company. From July 2001 to October 2008, Dr. Heron was Chair and Chief Executive Officer of Labcyte Inc., a private biotechnology company. Before joining Labcyte Inc., she spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, a biotechnology company, including the position of General Manager and Vice President of Sales and Marketing. Dr. Heron earned a B.S. in chemistry with highest distinction and a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University.
What is the salary of Elaine Heron?
As the Independent Director of Biomarin Pharmaceutical, the total compensation of Elaine Heron at Biomarin Pharmaceutical is $477,020. There are 10 executives at Biomarin Pharmaceutical getting paid more, with Jean-Jacques Bienaime having the highest compensation of $18,405,900.
How old is Elaine Heron?
Elaine Heron is 71, he's been the Independent Director of Biomarin Pharmaceutical since 2002. There are 1 older and 21 younger executives at Biomarin Pharmaceutical. The oldest executive at Biomarin Pharmaceutical Inc. is Alan Lewis, 74, who is the Independent Director.
What's Elaine Heron's mailing address?
Elaine's mailing address filed with the SEC is C/O VAXART, INC., 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Biomarin Pharmaceutical
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy a Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.
What does Biomarin Pharmaceutical do?
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
What does Biomarin Pharmaceutical's logo look like?
Complete history of Elaine Heron stock trades at Biomarin Pharmaceutical a Vaxart Inc
Biomarin Pharmaceutical executives and stock owners
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include:
-
Jean-Jacques Bienaime,
Chairman of the Board, Chief Executive Officer -
Henry Fuchs,
President - Worldwide Research & Development -
Jeff Ajer,
Executive Vice President, Chief Commercial Officer -
Jean-Jacques Bienaime M.B.A., MBA,
Chairman & CEO -
G. Eric Davis,
Executive Vice President, General Counsel, Secretary -
Dr. Henry J. Fuchs,
Pres of Worldwide R&D -
Dr. C. Greg Guyer Ph.D.,
CTO and Exec. VP of Global Manufacturing & Technical Operations -
Jeffrey Robert Ajer,
Exec. VP & Chief Commercial Officer -
Brian R. Mueller,
Exec. VP of Fin. & CFO -
Richard Meier,
Lead Independent Director -
Elaine Heron,
Independent Director -
Robert Hombach,
Independent Director -
Alan Lewis,
Independent Director -
Michael Grey,
Independent Director -
V. Bryan Lawlis,
Independent Director -
David Pyott,
Independent Director -
Dennis Slamon,
Independent Director -
Willard Dere,
Independent Director -
Elizabeth Anderson,
Independent Director -
Lon Cardon,
Chief Scientific Strategy Officer -
Andrea Acosta,
Chief Accounting Officer, Group Vice President -
C. Greg Guyer,
Chief Technical Officer, Executive Vice President of Global Manufacturing, Technical Operations -
Brian Mueller,
Chief Financial Officer, Executive Vice President -
Dr. Brinda Balakrishnan M.D., Ph.D.,
Group VP of Corp. & Bus. Devel. -
Philip Lo Scalzo,
Sr. VP & Chief Compliance Officer -
George Eric Davis,
Exec. VP, Gen. Counsel & Sec. -
Traci McCarty,
VP of Investor Relations -
Andrea L. Acosta,
Group VP & Chief Accounting Officer -
Daniel K Spiegelman,
EVP, Chief Financial Officer -
Athena Countouriotis,
Director -
Mark J Enyedy,
Director -
Barbara W. Bodem,
Director -
Robert Baffi,
President, Global Mfg/Tech Ops -
Cristin Hubbard,
EVP, Chief Commercial Officer -
Kathryn E Falberg,
Director -
William D Young,
Director -
Pierre Lapalme,
Director -
Jeffrey Landau,
Sr. Vice President, Admin. -
Gwynn Williams,
Director -
Steve Aselage,
SVP, Global Commercial Ops -
Christopher M Starr,
Sr. VP, Scientific Operations -
Franz L Cristiani,
Director -
Jeffrey H Cooper,
Chief Financial Officer -
Joseph Iii Klein,
Director -
Emil D Kakkis,
SVP, Business Operations -
Kenneth Bate,
Director -
Mark Wood,
VP, Human Resources -
John Urquhart,
Director -
Erich Sager,
Director -
Stuart J Swiedler,
SVP, Clinical Affairs -
Fredric D Price,
Chief Executive Officer -
Vijay B Samant,
Director -
Maykin Ho,
Director -
Mark J Alles,
Director -
Erin Burkhart,
GVP, Chief Accounting Officer -
Alexander Hardy,
Chief Executive Officer